California State Teachers Retirement System Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

California State Teachers Retirement System grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 13.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 876,268 shares of the biopharmaceutical company's stock after buying an additional 104,338 shares during the quarter. California State Teachers Retirement System owned 0.15% of Royalty Pharma worth $22,354,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in RPRX. Nissay Asset Management Corp Japan ADV lifted its position in shares of Royalty Pharma by 0.7% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock worth $1,238,000 after buying an additional 349 shares during the last quarter. Keene & Associates Inc. increased its holdings in shares of Royalty Pharma by 1.9% during the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock valued at $495,000 after acquiring an additional 370 shares during the last quarter. National Bank of Canada FI grew its holdings in Royalty Pharma by 21.8% in the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 371 shares during the last quarter. Blue Trust Inc. grew its position in Royalty Pharma by 31.3% in the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 376 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC grew its holdings in shares of Royalty Pharma by 1.1% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock worth $890,000 after purchasing an additional 380 shares in the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, May 20th. Morgan Stanley began coverage on shares of Royalty Pharma in a research report on Friday, May 16th. They set an "overweight" rating and a $51.00 target price on the stock. Finally, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $42.50.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock traded up $0.18 on Tuesday, hitting $33.44. 603,302 shares of the company traded hands, compared to its average volume of 3,517,315. The business has a 50-day simple moving average of $32.34 and a 200 day simple moving average of $30.50. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The stock has a market capitalization of $18.80 billion, a P/E ratio of 23.06, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.99 by $0.07. The firm had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Research analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a $0.22 dividend. The ex-dividend date is Friday, May 16th. This represents a $0.88 annualized dividend and a yield of 2.63%. Royalty Pharma's dividend payout ratio is presently 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.